Kaleido BioSciences, Inc. (OTC:KLDO)
Industry: Technology

OFF LIST - 1018 consecutive market days: OFF LIST as of 05/18/2012 Through 11/14/2016

Kaleido BioSciences, Inc. develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea. Kaleido BioSciences, Inc. has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; and a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Current Quote*
Last: $5.690
Change: 0.110
Book: $2.499
Volume: 55,625

As Of: 01/22 13:00 ET
*Quotes delayed by 20min.

Graphs for KLDO

3 Month Graph

6 Month Graph

1 Year Graph